M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer’s disease genes and improving memory

Claude-Henry Volmar\textsuperscript{a,b,1}, Hasib Salah-Uddin\textsuperscript{a,b}, Karolina J. Janczura\textsuperscript{a,b,2}, Paul Halley\textsuperscript{a,b,2}, Guerline Lambert\textsuperscript{a,b}, Andrew Wodrich\textsuperscript{a,b}, Sivan Manoah\textsuperscript{a,b}, Hindhi Patel\textsuperscript{a,b,}, Gregory C. Sartor\textsuperscript{a,b}, Neil Mehta\textsuperscript{a,b}, Nancy T. H. Miles\textsuperscript{a,b}, Sachi Desse\textsuperscript{a,b}, David Dorcuis\textsuperscript{a,b}, Michael D. Cameron\textsuperscript{c}, Shaun P. Brothers\textsuperscript{a,b}, and Claes Wahlestedt\textsuperscript{a,b,1}

\textsuperscript{a}Center for Therapeutic Innovation, Miller School of Medicine, University of Miami, Miami, FL 33136; \textsuperscript{b}Department of Psychiatry, Miller School of Medicine, University of Miami, Miami, FL 33136; and \textsuperscript{c}Department of Molecular Medicine, Scripps Florida, Jupiter, FL 33458

Edited by Li-Huei Tsai, Massachusetts Institute of Technology, Cambridge, MA, and accepted by Editorial Board Member Susan G. Amara September 2, 2017 (received for review May 8, 2017)

Alzheimer’s disease (AD) comprises multifactorial ailments for which current therapeutic strategies remain insufficient to broadly address the underlying pathophysiology. Epigenetic gene regulation relies upon multifactorial processes that regulate multiple gene and protein pathways, including those involved in AD. We therefore took an epigenetic approach where a single drug would simultaneously affect the expression of a number of defined AD-related targets. We show that the small-molecule histone deacetylase inhibitor M344 reduces beta-amyloid (Aβ), reduces tau \textsuperscript{396}phosphorylation, and decreases both beta-secretase (BACE) and APOE\textsubscript{ε}gene expression. M344 increases the expression of AD-relevant genes: BDNF, α-secretase (ADAM10), MINT2, FE65, REST, SIRT1, BIN1, and ABCA7, among others. M344 increases sAPPx and CTfrx APP metabolism production, both cleavage products of ADAM10, concordant with increased ADAM10 gene expression. M344 also increases levels of immature APP, supporting an effect on APP trafficking, concurrent with the observed increase in MINT2 and FE65, both shown to increase immature APP in the early secretory pathway. Chronic i.p. treatment of the triple transgenic (APP/PS1\textsubscript{M146V}/TauP301L) mice with M344, at doses as low as 3 mg/kg, significantly prevented cognitive decline evaluated by Y-maze spontaneous alternation, novel object recognition, and Barnes maze spatial memory tests. M344 displays short brain exposure, indicating that brief pulses of daily drug treatment may be sufficient for long-term efficacy. Together, these data show that M344 normalizes several disparate pathogenic pathways related to AD. M344 therefore serves as an example of how a multitargeting compound could be used to address the polygenic nature of multifactorial diseases.

Significance

Hundreds of failed clinical trials with Alzheimer’s disease (AD) patients over the last fifteen years demonstrate that the one-target-one-disease approach is not effective in AD. In silico, structure-based, multitarget drug design approaches to treat multifactorial diseases have not been successful in the context of AD either. Here, we show that M344, an inhibitor of class I and IIB histone deacetylases, affects multiple AD-related genes, including those related to both early- and late-onset AD. We also show that M344 improves memory in the 3xTg AD mouse model. This work endorses a shift to a multitargeted approach to the treatment of AD, supporting the therapeutic potential of a single small molecule with an epigenetic mechanism of action.

Author contributions: C.-H.V., H.S.-U., K.J.J., P.H., and C.W. designed research; C.-H.V., H.S.-U., K.J.J., P.H., G.L., A.W., S.M., N.H.P., G.C.S., N.M., N.T.H.M., S.D., D.D., and M.D.C. performed research; C.-H.V., H.S.-U., K.J.J., P.H., A.W., S.M., N.H.P., G.C.S., N.M., M.D.C., S.P.B., and C.W. analyzed data; C.-H.V. and C.W. wrote the paper; C.-H.V., H.S.-U., P.H., and C.W. conceived of the project; and S.P.B. and C.W. provided financial support. The authors declare no conflict of interest.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1707544114/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1707544114

Link to publisher version

Published online October 9, 2017 | E9135–E9144
astrogliosis, and proinflammatory cytokines) as root causes of AD (15–19).

Several AD susceptibility genes, identified in patients through linkage and genome-wide association studies, suggest that AD is a complex polygenic disease (5, 20–23). Due to the polygenicity of AD and the vast number of failures with the single-target approach, many have hypothesized that it will be necessary to utilize combination therapies, and/or treatment at preclinical or prodromal stages for this disease. Here, we tested this hypothesis with an epigenetic approach where we hypothesized a single small molecule could simultaneously affect the expression of many AD-related drug targets, thus bypassing the need for drug combinations. Moreover, since gene expression changes through the remodeling of chromatin play an important role in memory formation (24–27), and epigenetic changes are widely reported in AD brain (28–31), such an epigenetic-directed compound could also prevent memory decline in an AD mouse model.

We provide data describing that the histone deacetylase inhibitor (HDACi) M344 (4-((diethylamino)-N-[7-(hydroxamino)-7-oxoheptyl]benzamid) modifies several of the AD-related pathways and thus holds some therapeutic potential. M344 was first synthesized in 1999 by Jung et al. (32) and, while little studied compared with many other HDACis, it was reported to significantly increase survival motor neuron 2 (SMN2) gene expression—a gene associated with the severity of proximal spinal muscular atrophy, an orphan disease (33, 34). In the experiments described below we show that M344 favorably addresses a number of key genes reported to be involved in early- and late-onset AD pathogenesis and attenuates cognitive decline in a chronically treated AD mouse model.

Results

Compound Selectivity Profile. Since little is known about the HDAC selectivity profile of M344 (32), we tested its potency at inhibiting all 11 known zinc-dependent HDACs. The half-maximal inhibition (IC50) concentration of M344 was calculated for each HDAC with a ten-point concentration response curve in duplicates, using titration of 1:3 dilutions (BPS Bioscience). Each HDAC was also inhibited by an appropriate positive control, such as vorinostat (suberoylanilide hydroxamic acid) for HDACs 1, 2, 3, and 8) and IIB (HDACs 6 and 10) in the submicromolar to the micromolar range (Table 1), suggesting selectivity for these classes. Detailed concentration curves are provided in Fig. S1.

Table 1. M344 HDAC selectivity profile

| HDAC | M344 IC50, μM | Reference |
|------|--------------|-----------|
| HDAC1 | 0.048 | 0.082 (SAHA) |
| HDAC2 | 0.12 | 0.19 (SAHA) |
| HDAC3 | 0.032 | 0.046 (SAHA) |
| HDAC4 | 26.80 | 2.21 (TSA) |
| HDAC5 | 15.82 | 1.18 (TSA) |
| HDAC6 | 0.0095 | 0.027 (SAHA) |
| HDAC7 | 17.09 | 1.34 (TSA) |
| HDAC8 | 1.34 | 0.61 (TSA) |
| HDAC9 | 48.80 | 5.20 (TSA) |
| HDAC10 | 0.061 | 0.089 (SAHA) |
| HDAC11 | >100 μM | 18% at 100 μM |

Summary of half-maximal inhibitory concentration in biochemical activity assay for each zinc-dependent HDAC. Each sample was tested in duplicate, with a 10-point dose–response of one to three dilutions, starting at 100 μM. M344 shows greater potency at inhibiting classes I and IIB HDACs.

Effects of M344 on AD-Related Genes. Using NanoString nCounter technology (35, 36), we investigated the effects of M344 on 71 AD-related genes after 48 h treatment of HEK cells over-expressing the familial APP Swedish double mutation (KM670/671NL) (5)—HEK/APPsw—a well-characterized AD cell model (6, 37, 38). The heat map generated from this experiment illustrates the differential expression of genes after M344 treatment. With a false discovery rate (FDR) less than 5%, several AD-related and neuroplasticity genes are significantly up- and down-regulated by M344 (Fig. 1 and Table S1). Interestingly, several genes reported to be neuroprotective when up-regulated in AD are increased by M344 treatment. Among these genes with increased expression are brain-derived neurotrophic factor (BDNF) (3.4-fold, P < 0.0001), neuregulin (NRG1) (4.8-fold, P < 0.0001), NAD-dependent deacetylase sirtuin-1 (SIRT1) (1.6-fold, P < 0.0001), a disintegrin and metalloprotease 10 (ADAM10) (1.40-fold, P < 0.0001), ADAM19 (1.5-fold, P < 0.01), and repression element-1 silencing transcription factor (REST) (1.2-fold, P < 0.0001). Of particular interest are the ADAM family members and SIRT1, which promote non-amyloidogenic APP processing to be thought in both early- and late-onset AD.

A similar trend toward nonamyloidogenic processing and anti-AD protection is also observed in significantly down-regulated genes depicted in the NanoString nCounter heat map. Among them are glycogen synthase kinase 3-β (GSK3β) (−1.4-fold, P < 0.0001), Nicastrin (NCSTN) (−3.2-fold, P < 0.0001), anterior pharynx-defective 1 (APH1) (−1.8-fold, P < 0.0001), β-site APP-Cleavage Enzyme 1 (BACE1) (−1.7-fold, P < 0.0001), BACE2 (−3.2-fold, P < 0.0001), cluster of differentiation 40 ligand (CD40L) (−1.5-fold, P < 0.01), and C-X-C Motif Chemokine Receptor 2 (CXCR2) (−2.0-fold, P < 0.0001), which are all genes hypothesized to counter AD phenotype and pathogenesis (37, 39–41). In the case of late-onset AD (LOAD) genes, apolipoprotein-E-e4 (APOE4) is reduced (−1.8-fold, P < 0.0001), which may be therapeutically beneficial (21, 42). There is also a significant increase observed with the bridging integrator 1 (BIN1) (2.2-fold, P < 0.0001)—reported to increase tau pathology and BACE1-dependent processing of APP (43, 44). Adenosine triphosphate-binding cassette subfamily A member 7 (ABCA7) is also up-regulated (2.1-fold, P < 0.0001), which is thought to be protective. ABCA7 loss of function is a risk factor for LOAD, and deficiency in ABCA7 increases production of Aβ (45, 46). Several Alzheimer’s-related genes tested such as complement receptor 1 (CR1), interleukin 10 (IL10), cluster of differentiation 33 (CD33) and APOE-e2 showed no change in gene expression by M344, showing that this molecule does not randomly affect all genes.

M344 Effects on α- and β-Secretases and APP Processing. With the observation of significant increases in several α-secretases and decreases in β-secretases in the NanoString experiments we confirmed the effect of M344 on ADAM10 and BACE1 (the two predominant α- and β-secretases involved in brain APP processing) using real-time (RT) qPCR and Western blotting (Fig. 2). Treatment of HEK/APPsw cells with 10 μM of M344—a concentration that will inhibit target HDACs (Table 1), and which we show displays no toxicity (Fig. 3)—resulted in significant increase in ADAM10 gene expression (1.80-fold, P < 0.0001) and protein levels (121.0%, P < 0.0001), similar to results obtained with the NanoString. BACE1 gene expression (−3.6-fold, P < 0.0001) and protein level (−58.1%, P < 0.0001) also were confirmed to decrease after treatment of HEK/APPsw cells with M344, replicating the NanoString results (Fig. 2).

Because we observed significant regulation of several APP-cleaving secretases after treatment of HEK/APPsw cells with M344, we hypothesized that there will be an increase in full-length APP (holo-APP) in the presence of M344. Unexpectedly,
we observed a significant increase (36.19%, P < 0.0001) of immature APP after treatment with M344 (Fig. 2). We also investigated the levels of sAPPα and CTF-α, two APP metabolites that result from α-secretase cleavage of APP, and observed significant increases (118.06%, P < 0.0001 for sAPPα and 35.96% for CTF-α, P < 0.05), functionally supporting the increase of α-secretases and decrease in β-secretase observed in the NanoString, RT-qPCR, and with Western blot. As an additional control, we used garcinol, a histone acetyl transferase (HAT) inhibitor of p300 and PCAF (47), hypothesizing that a HAT inhibitor would cause opposite effects to those observed with M344. Garcinol caused significant increases in both mature APP (37.98%, P < 0.01) and BACE1 (54.3%, P < 0.0001), whereas M344 treatment resulted in significant decreases in these APP processing parameters, as described above. Moreover, garcinol treatment caused sAPPα to significantly decrease (~33.6%, P < 0.01) compared with a significant increase of 118% observed with M344, further supporting a histone acetylation-dependent mechanism. We also show, in these cells, that M344 significantly increases acetylation of H3K27 (24.53%, P < 0.01) and H4K12 (95.5%, P < 0.05) after 48 h of treatment (Fig. S2). We also show a time-dependent increase of both pan-lysine and H4K12 acetylation (Fig. S3). We further support an HDAC-dependent effect by shRNA silencing of class I and IIb HDACs—targets of M344—and show significant increases in CTFα, ADAM10, and holo-APP protein levels with silenced HDACs 1, 2, 3, and 6 (Fig. S4).

**Effects of M344 on Aβ Accumulation.** Since there was a shift toward nonamyloidogenic processing, we hypothesized that Aβ level would decrease in the presence of M344. We indeed observed a significant decrease of Aβ in HEK/APPsw cells treated with 10 μM of M344. To further validate an HDAC mechanism we tested several other HDAC inhibitors that also significantly reduced Aβ40/Aβ42 accumulation in these cells (Fig. S4). We then verified that these effects were caused by an effect on Aβ accumulation and not due to cytotoxicity by performing a cell viability assay (CellTiter-Glo; Promega) on treated cells versus controls (Fig. 3B). The cell viability results demonstrate that cells treated with M344 showed no cell death and that M344 appears to be less toxic than the other HDAC inhibitors tested.

**Effects of M344 on APP Trafficking Genes.** Considering immature APP (N-glycosylated) is significantly increased with M344 treatment (Fig. 2 and Fig. S5), and with the knowledge that immature APP localizes mostly to the early protein secretory pathway, then matures upon trafficking to the late secretory pathway where it is cleaved by β-secretase, we hypothesized that M344 affects gene expression of proteins involved in APP trafficking. MINT2 (APB2, X11L1) and FE65 (APBB1) expressions are two important regulators of APP endocytosis shown to increase immature APP in the early secretory pathway, subsequently preventing APP interaction with BACE in the late endosome (2, 48). Interestingly, we observed significant increases of both MINT2 (2.7-fold, P < 0.01) and FE65 (1.7-fold, P < 0.05) gene expression in HEK/APPsw cells treated with M344 (Fig. 4A and B). This acetylation further support the anti-AD profile of M344 because increased MINT2 or FE65 has been linked to decreased Aβ production and less amyloid deposition in APP transgenic mice brain (49, 50). We tested several other HDAC inhibitors that also significantly reduced Aβ40/Aβ42 accumulation in these cells (Fig. S4).

**M344 Effects on Neuroprotective Genes BDNF and REST.** Treatment of HEK/APPsw cells for 48 h revealed significant increases of both BDNF (7.1-fold, P < 0.0001) and REST (4.2-fold, P < 0.001) gene expression (Fig. 4 C and D) and of BDNF protein expression (42.3%, P < 0.01) (Fig. 4E). Due to lack of a reliable REST antibody we were unable to determine REST protein levels. M344 also increased REST gene expression in control HEK-293 cells, although to a lesser extent compared with HEK/APPsw cells treated with M344 (Fig. 4A and B). The cell viability results demonstrate that cells treated with M344 showed no cell death and that M344 appears to be less toxic than the other HDAC inhibitors tested.

**M344 Is Brain-Penetrant and Increases Histone Acetylation in Vivo.** We conducted pharmacokinetic studies with 10 mg/kg of M344 injected i.p. Fig. 5A and B show that M344 concentrations peak rapidly at 15 min in both plasma and the brain. Of note, M344 reaches brain concentrations of 47 ng/mL (P < 0.05), a value equivalent to 0.13 μM that is sufficient to inhibit HDACs 1, 2, 3, 6, and 10 as shown in Table 1 and Fig. S1. Fig. 5 C–E show that M344 significantly increases acetylation of histone H4K12 in the frontal cortex, but not in the cerebellum. Fig. 5F shows that...
after 15 min of 10 mg/kg i.p. injection there is ~1.4% brain/plasma ratio with 3.1 ± 0.71 μM free concentration and 0.39 ± 0.04 free fraction of M344 in plasma.

**Effects of M344 on Y-Maze Spontaneous Alternation in 3xTg APP<sub>sw</sub>/PS1<sub>M146V/Tau<sub>P301L</sub></sub> Mice.** We then tested M344 in the 3xTg AD mice overexpressing APP<sub>sw</sub>, Tau<sub>P301L</sub>, and Presenilin 1 (PS1, PSEN1) (52) using a battery of behavioral tests. In 3xTg AD mice that were repeatedly i.p. treated with M344 (for ~4 mo, as described in Materials and Methods) we observed a dose-dependent increase in Y-maze spontaneous alternation (3 mg/kg, 67.0%, P < 0.05; 10 mg/kg, 71.2%, P < 0.01) compared with vehicle controls (Fig. 6A). No difference in total number of arm entries was observed (Fig. 6B), demonstrating no deficits in motor function and supporting that the increased spontaneous alternation observed in treated mice is due to increased spatial memory and willingness to explore new environments.

**Effect of M344 on Open Field Behavior and Novel Object Recognition.** We further tested the effects of M344 on locomotor behavior using the open field test. No significant difference was observed between M344-treated animals and controls for distance traveled or velocity (Fig. 6 C and D). Having observed no difference in locomotor behavior in the treated and control mice, we proceeded to test for novel object recognition in the same open field arena. In this test, at both 3 mg/kg and 10 mg/kg doses, treated mice significantly outperformed control mice in novel object exploration duration (3 mg/kg: 66.5%, P < 0.05; 10 mg/kg: 57.2%, P < 0.05) (Fig. 6E) and novel object exploration frequency (3 mg/kg: 47.8%, P < 0.05; 10 mg/kg: 47.3%, P < 0.05) (Fig. 6F).

**Effects of M344 on Barnes Maze Performance.** We further evaluated spatial memory in the 3xTg AD mice treated with 3 mg/kg and 10 mg/kg of M344 using a Barnes maze. We observed significantly fewer errors in acquisition trials 3 and 5 for mice that received 10 mg/kg of M344 (P < 0.05) and fewer errors in trial 5 for those treated with 3 mg/kg (P < 0.05) compared with vehicle-treated controls (Fig. 6G). After 24 h of rest, in the probe trial both mice treated with M344 committed fewer errors than controls (3 mg/kg: −44.6%, P < 0.05; 10 mg/kg: −53.8%, P < 0.01) (Fig. 6H), indicating increased spatial memory in these mice.
Effects of M344 on AD-Like Pathology in the Hippocampus of 3xTg AD Mice. M344 significantly decreased Aβ1–42 in the hippocampus of mice treated with doses of 3 mg/kg (−42.7%, P < 0.05) and 10 mg/kg (−35.6%, P < 0.05) (Fig. 7A). M344 significantly increased ADAM10 gene expression only in the hippocampus of mice treated with 10 mg/kg (2.1-fold, P < 0.05) (Fig. 7B). Only treatment with 3 mg/kg of M344 resulted in a significant decrease of BACE1 gene expression (−1.8-fold, P < 0.05) (Fig. 7C). We also observed significant decrease in phosphorylation of tau at Ser199—a residue found in paired helical filaments in brain neurofibrillary tangles of AD patients—at both 3 mg/kg (−58.2%, P < 0.01) and 10 mg/kg (−57.7%, P < 0.01) (Fig. 7D).

Discussion

We show that the HDAC inhibitor M344 is a potent inhibitor of class I and class II HDACs that simultaneously regulates the expression of several high-priority genes related to EOAD, LOAD, synaptic plasticity, and neuroprotection in the HEK/APPsw cell model (Table 1, Fig. 1, and Fig. S1). In support of the gene expression data, we show that M344 significantly reduces Aβ1–42/Aβ1–40 ratio with no negative effects on cell viability, while also appearing to have a better in vitro toxicity profile than other HDAC inhibitors tested (Figs. 1–3). A mechanism that can explain this decrease in Aβ1–42/Aβ1–40 ratio is the M344-induced down-regulation of γ-secretase complex components NCSTN and APH1 (Fig. 1), which would reduce APP cleavage at the relevant sites. However, down-regulating the γ-secretase complex—comprising PSEN1 or PSEN2, PEN2, NCSTN, and APH1—is troublesome since γ-secretase also cleaves NOTCH, a transmembrane protein whose cleavage products are reported to promote neurogenesis. Inhibition of NOTCH processing has been cited as a possible cause of the recent γ-secretase inhibitor clinical trial failures (12–14). Although both NCSTN and APH1 are significantly down-regulated with M344, we would not expect a decrease in the processing of NOTCH since M344 also increases other components of the complex in PEN2, PSEN1, and PSEN2 (Fig. 1), which have been demonstrated to be sufficient for γ-secretase-dependent NOTCH processing (53). The decrease in Aβ1–42/Aβ1–40 ratio could also be the result of a combined effect of decreasing the expression of CXCR2, NCSTN, and APH1. Deletion of CXCR2 has been reported to reduce γ-secretase cleavage of APP (40). The effect of M344 or other HDACs on CXCR2-mediated γ-secretase APP processing is not known and deserves further investigation. Because we only observed significant reduction of Aβ1–42/Aβ1–40 ratio in cells silenced for HDAC3 (Fig. S4F), it may be worth investigating the effects of HDAC3 function on CXCR2 and γ-secretase components.

In cases of EOAD involving APP mutations such as APPsw, the overproduction of Aβ is often due to excess cleavage by β-secretases (6). Here, we show that compound M344 significantly reduces β-secretases BACE1 and BACE2, concurrent with observed decreases in the accumulation of Aβ1–42 (Figs. 2, 3, and 7), indicating that HDAC inhibition is an alternative approach to BACE1 inhibition. Of note, a BACE1 inhibitor, verubecestat (MK-8931), recently failed in phase III trials (10). Thus, an epigenetic compound that is able to reduce BACE1-mediated metabolites as one of its targets in the AD network represents a novel way to regulate BACE activity, which has been challenging (54).

The up-regulation of α-secretase has been proposed as a highly desirable therapeutic target for AD. Here, we report that the M344 compound also significantly increases the gene expression of α-secretases ADAM10 and ADAM19, concurrent with the observed increases in the metabolites sAPPα and CTFα after M344 treatment (Fig. 2 and Fig. S6). Similar effects have been reported with the HDAC inhibitor apicidin up-regulating the expression of ADAM10 via an HDAC2/3 mechanism involving the transcription factor USF-1 (55). Here we show in
HEK/APP<sub>sw</sub> cells that it is possible that the effect on ADAM10 is mediated by HDACs 1, 2, 3, and 6 because M344 inhibits these HDACs, and silencing experiments caused increased protein levels of ADAM10 and CTF<sub>α</sub> (Fig. S4A and B). We also observe a significant increase in SIRT1 expression, which has been shown to promote ADAM10 cleavage of APP (56). Thus, it is also possible that the increased nonamyloidogenic processing induced by M344 is partially a SIRT-1-mediated effect, making M344 an HDAC inhibitor affecting both zinc-dependent and class III NAD-dependent HDACs.

We also observed, in HEK/APP<sub>sw</sub> cells, significant increases in the APP trafficking genes MINT2 and FE65, and of the neuroprotective genes BDNF, NRG1, and REST, all genes reported to be beneficial against AD if up-regulated (Fig. 4). Increased REST expression correlates with healthy aging, cognitive preservation, and longevity (51). Our findings support studies by others that have shown that the HDAC inhibitor SAHA and inhibition of HDACs 2 and 3 increase BDNF gene expression (57, 58). Further, high concentrations—0.8–5 mM—of β-hydroxybutyrate increase BDNF expression via inhibition of HDACs 2 and 3 (59). Since M344 inhibits these two HDACs, M344-mediated induction of BDNF expression (Fig. 4C and E and Fig. S7) is likely due to activity on HDACs 2 and 3. To our knowledge, inhibition of class I and IIb HDACs has not previously been shown to increase the expression of APP trafficking genes MINT2 and FE65 involved in decreased APP cleavage.

Among LOAD-related genes, M344 decreases the expression of APOE<sub>e4</sub>—for which the presence of just one e4 allele represents the greatest risk factor of developing AD (21, 42). M344 also increases the expression of BIN1—the second-greatest reported LOAD risk factor (43, 44). Effects of M344 at both genes would be expected to be protective. Increased APOE<sub>e4</sub> also elevates Aβ accumulation (60). Decreased BIN1 has been reported to promote tau pathology (43). Similarly, M344 also up-regulates other LOAD risk-factor genes (i.e., ABCA7 and PICALM) whose deficiencies have been shown to promote AD pathology (43–46, 61). M344 also shows significant decrease of CD40L, the cognate ligand of CD40, which has been proposed as a diagnostic biomarker in LOAD (62), and whose signaling has been reported to increase Aβ-induced microglial

![Fig. 5](https://www.pnas.org/cgi/doi/10.1073/pnas.1707544114)
M344 causes significant increases of H4K12 acetylation in the cortex of mice, but not in the cerebellum (Fig. 5). Deregulation of H4K12 acetylation is linked to cognitive impairment associated with aging, and increased acetylation at that mark may rescue memory (66, 67). Our data with the 3xTg mice indicate that one dose per day of M344 at 3 mg/kg or 10 mg/kg for 4 mo is enough to trigger an anti-AD profile without observable adverse effects. It is plausible that over the course of 4 mo the relatively low 

We show that treatment of the well-established 3xTg AD mouse model with doses as low as 3 mg/kg of M344 results in improvement of learning and memory in different behavioral tests, with no effects on locomotor activity (Fig. 6). Indeed, we observed significant increases in Y-maze spontaneous alternation, a measure of hippocampus-dependent spatial memory and the willingness of mice to explore new environments (68, 69). We also observed superior performance of the 3xTg AD mice treated with M344 in both the novel object recognition test and the probe test of the Barnes maze—a spatial memory test similar to the Morris water maze. Interestingly, Tg2576 AD mice treated with 25 mg/kg and 50 mg/kg of SAHA (also known as vorinostat), a compound closely related to M344, has shown positive effects on synaptic plasticity at the long-term potentiation level, but not behaviorally in the fear conditioning paradigm (65). Such a discrepancy with our study could be due to the different tests used, the animal model, age of animals, and length of treatment. In a different animal model (aged APP/PS1 mice), Kilgore et al. (70) saw improvement of cognitive behavior with i.p. injections of 50 mg/kg of SAHA, supporting an HDAC class I inhibition approach in their paper. Another study using SAHA administered 2 mg/d orally to aged (10-mo-old) APP-PSI-21 AD mice observed partial improvement of spatial memory, reduction of transcriptional inflammatory response, and increased H4K12 acetylation, with no significant differences observed in Aβ plaques (66). Although they used different animals and paradigms, focusing more

activation and plaque-associated tau phosphorylation in AD mice (39, 63). The M344-mediated reduction in CD40L likely results in interruption of CD40-CD40L interaction. Such a disruption of CD40-CD40L signaling has been shown to be beneficial in reducing AD-like pathogenesis and increase cognition in AD mice (37, 39, 64).

We show that i.p. treatment of mice with 10 mg/kg of M344 causes a maximum plasma concentration of ~8.8 μM (C_{max}) and gets into the brain with a peak of about 0.13 μM (C_{max}) after 15 min of treatment. That concentration is high enough to reach the IC_{50} values of HDAC1 (0.048 μM), HDAC2 (0.12 μM), HDAC3 (0.032 μM), HDAC6 (0.0095 μM), and HDAC 10 (0.061 μM) but not HDAC8 (1.34 μM). With a low molecular weight (307.4), a LogP of ~1.06, as well as high free fraction and free concentration levels in plasma (Fig. 5F), M344 has the properties of a brain-penetrant compound. The fact that brain plasma ratio ranges from 1.4% at 15 min to 1.7% at 30 min suggests quick removal by brain Pgp and Bcrp efflux transporters, similar to what is observed with SAHA, a related compound (65). Despite its high rate of removal in the brain,
on aging and the transcriptome, the Kilgore et al. (70) and the Benito et al. (66) studies both support our findings that targeting several HDACs with a small-molecule inhibitor provides a multifaceted approach to normalize AD-related genes. The lack of difference in Aβ levels observed in Benito et al. (66) is likely due to three main differences between the studies: (i) the length of treatment (4 wk versus 4 mo in our case), (ii) the stage of AD-like symptoms of the animals at the start of treatment (postdisease state versus presymptomatic), and (iii) the Aβ measurement technique (immunohistochemistry versus ELISA). Overall, the two studies are concordant. Other studies with HDACis such as 200 mg/kg sodium 4-phenylbutyrate in Tg2576 AD mice (71) or 50 mg/kg of the class II mercaptoacetamide compound W2 in 3xTg AD mice (72) also show positive effects on memory, further suggesting feasibility of the approach. However, somewhat in contrast, treatment of 3xTg AD mice with even low dose of M344 significantly decreases levels of the molecular targets BACE1, Aβ1-42, and phospho-tau Ser396 in the hippocampus. Separate studies have reported other HDACis to be beneficial for AD, either due to induced increase in BDNF gene expression, or decrease in GSK3β expression, or decrease in tau phosphorylation, or decrease in Aβ accumulation to increase cognition in AD mouse models (31, 70, 73–77). Here, we propose that such effects are due to the multitarget nature of these HDAC inhibitors, similarly to M344, and not to a single target.

It is important to emphasize that most of the work performed with HDACis on AD models in the literature has been conducted on old animals, after AD-like disease onset. This approach has yielded poor results in AD patients. Many clinical trial failures have been on old patients with mild to moderate disease, and reversing the pathology may not readily result in alleviation of symptoms. As the field is moving toward trials on preclinical/prodromal AD populations (10), we opted to start treatment of mice before the development of disease. Since 3xTg mice have been reported to present overt molecular and behavioral AD-like pathology at the age of 6 mo, we started treatment of 3-mo-old presymptomatic 3xTg mice 5 d a week for about 4 mo to evaluate the possibility of low doses of this drug as a preventive measure for AD. This method was successful at preventing AD-like pathogenesis at molecular and behavioral levels. This study does not, however, show whether M344 would continue to be beneficial for longer-term studies (i.e., beyond 7 mo of age when AD-like symptoms are more severe). Other limitations of the work presented here include the possibility of HDACis increasing the acetylation of proteins other than histones, such as tau acetylation reported to be a promoter of tau pathology (78, 79). We have, for instance, shown that treatment of HEK/APPsw cells with M344 results in an approximately six-fold increase in acetylated α-tubulin (Fig. S8), a target of HDAC6 (80). However, other possible mechanisms are beyond the scope of the present study showing that a multitarget approach is a plausible alternative to the one-target-one-disease paradigm in the context of AD.

Finally, pharmacokinetic studies demonstrated that M344 is brain-penetrant, and that our in vivo dosing regimens resulted in sufficiently high CNS concentrations (comparable to the concentrations required to affect gene expression in vitro), but that the drug clears rapidly from plasma and brain. We therefore suggest that drug efficacy relates to Cmax (discussed above) and that prolonged daily exposure is likely not required. The observations that (i) in vivo efficacy was observed with much lower doses of this HDACi than typically used in mouse models of cancer and other CNS disorders (81, 82) and that (ii) short periods of high brain exposure seem to be sufficient for efficacy indicate that it may be possible to avoid adverse effects in possible future attempts to use M344 (or related compounds) to treat humans with AD or related disorders.

**Conclusion**

Using a multifactorial approach to fight a multifactorial disease is necessary. Since the single-target approach has been essentially unsuccessful to date in the treatment of AD, we aimed to use a broader-acting molecule to address the polygenic nature of this disease. In this paper, using an epigenetic approach, we show that it is possible to use one drug compound that simultaneously addresses several aspects of AD, including down- and up-regulation of key AD and neuroprotective genes. We demonstrated that M344, displaying sufficient but transient brain exposure, can prevent memory impairment in the 3xTg (APPsw/PS1ΔE9/ M146L/P301L) AD mouse model. Effectiveness in vivo doses of this HDAC inhibitor appear to be much lower than those typically used in animal models for cancer, and brief daily brain exposure seems sufficient. More work is needed with other small-molecule epigenetic compounds to identify the ideal anti-AD profile.

**Materials and Methods**

Detailed materials and methods are provided in SI Materials and Methods. Below are brief descriptions.

**Cell Culture.** HEK (HEK-293) cells were purchased from ATCC. They were cultured under standard conditions (37 °C, 5% CO2, 95% air) in Advanced DMEM supplemented with 10% (vol/vol) FBS, penicillin (100 U/mL), streptomycin (100 μg/mL), and Primocin (100 μg/mL). HEK cells overexpressing APP with the Swedish mutation (HEK/APPsw) were a gift from Dennis Selkoe, Brigham and Women's Hospital and Harvard Medical School, Boston, and were cultured in the same media as the HEK-293 cells supplemented with 250 μg/mL of G418 as a selection agent.

**NanoString Gene Expression Analysis.** For NanoString experiments, cells were treated with either 10 μM of M344 in 0.2% DMSO buffer or 0.2% DMSO buffer alone, in T-75 flasks (n = 6). Total RNA was extracted and then used to perform NanoString experiments described in detail by our group (83). The nCounter analysis system (NanoString Technologies) was used to quantify target RNA molecules using these color-coded molecular barcodes. Genes whose fold-change expression was statistically significant and FDR was less than 5% were used for further analysis. A P value threshold was set at 0.05.

**HDAC Activity Assay.** The selectivity profile of M344 was determined biochemically by performing activity assays in duplicate with each of the 11 zinc-dependent HDACs at 10-point 1:3 dilutions, starting at 100 μM (BPS Biosciences). SAHA was used as a positive control for HDACs 1, 2, 3, 6, and 10 since it is known to inhibit those enzymes. TSA was used as a positive control for HDACs 4, 5, 7, 8, 9, and 11 as it has been reported to inhibit these HDACs. All HDAC substral buffer, and developer were from BPS Biosciences. Fluorescence signal was measured at 360-nm excitation and 460-nm emission using a Tecan Infinite M1000 microplate reader. Curves were generated with GraphPad Prism 6.0, using a four-parameter non-linear curve fit to determine the concentration causing IC50 values.

**ELISAs and Western Blots.** Aβ1-40 and Aβ1-42 were measured from the media and from brain tissue by ELISA with the Novex kit (Life Technologies). An AlphaLISA kit from PerkinElmer was also used to measure Aβ1-42 levels in cells. The phosphorylation level of tau at Ser396 was measured using an ELISA kit from Thermo Fisher Scientific. All of the kits were used per the manufacturer’s instructions. For Western blots, electrophoresed proteins were transferred onto PVDF membranes. All of the primary antibodies were used at 1:1,000 dilution. Membranes were developed using the Clarity ECL detection reagents (Bio-Rad), visualized and then quantified by densitometry, using the Image J software from the NIH.

**RT-qPCR.** After total RNA extraction, cDNA was synthesized with random hexamers and Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase. Extracted cDNA was used for RT PCR with primers and Taqman Master Mix from Life technologies/Thermo Fisher Scientific. Samples were then amplified for 40 cycles using the Applied Biosystems FAST Real-Time PCR Detection System 7900HT or the Applied Biosystem Quastudio Flex Real-Time PCR System and analyzed with the SDS Real-Time PCR analysis software (Applied Biosystems). The results presented are based on fold change using the 2^-ΔΔCT method.
1. Alzheimer’s Association (2016) 2016 Alzheimer’s disease facts and figures. Alzheimers Dement 12:459-509.
2. Schubert D, et al. (2017) Intracellular trafficking of the amyloid β-protein precursor (APP) regulated by novel function of X11-like. PLoS One 6:e22108.
3. Tomita S, Kiriya Y, Suzuki T (1998) Cleavage of Alzheimer’s amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway. Identification of intracellular compartments in which APP cleavage occurs without using toxic agents that interfere with protein metabolism. J Biol Chem 273:6277–6284.
4. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 297:353–356.
5. Mullan M, et al. (1992) A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of β-amyloid. Nat Genet 1:345–347.
6. Haass C, et al. (1995) The Swedish mutation causes early-onset Alzheimer’s disease by β-secretase cleavage within the secretory pathway. Nat Med 1:1291–1296.
7. Muratore CR, et al. (2014) The familial Alzheimer disease APPV717 mutation alters APP processing and Tau expression in iPS-derived neurons. Hum Mol Genet 23:3523–3536.
8. Hooli B, Tanzi RE (2016) The genetic basis of Alzheimer’s disease. Developing Therapeutics for Alzheimer’s Disease: Progress and Challenges, Wolfe MS, ed (Academic, Boston), pp 23–31.
9. Jonsson T, et al. (2012) A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488:96–99.
10. Mullard A (2017) BACE inhibitor bust in Alzheimer trial. Nat Rev Drug Discov 16:155.
11. Amanatkar HR, Papagiannopoulos B, Grossberg GT (2017) Analysis of recent failures of disease modifying therapies in Alzheimer’s disease suggesting a new methodology for future studies. Expert Rev Neurother 17:7–16.
12. Extance A (2010) Alzheimer’s disease failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 9:749–751.
13. Crum CI, et al. (2012) B20:708,163 targets presenilin and lacks notch-sparing activity. Biochemistry 51:7209–7211.
14. D’Onofrio G, et al. (2012) Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Discov 7:19–37.
15. Swerdlow RH, Burns JM, Khan SM (2010) The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers Dis 20:5265–5279.
16. Mohandas E, Rajmohan V, Raghunath B (2009) Neurobiology of Alzheimer disease. Wien Med Wochenschr 120:101–122.
17. Desikan RS, et al. (2017) Genetic assessment of age-associated Alzheimer disease risk. J Neurosci 35:15062–15072.
18. Corder EH, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Nat Genet 3:133–138.
19. de la Torre JC (2010) The vascular hypothesis of Alzheimer disease. Nat Rev Neurol 6:1492–1499.
20. Pastori C, et al. (2014) BET bromodomain proteins are required for glioblastoma cell spreading. Epigenetics 9:611–620.
21. Vlcek C, Ait-Ghezala G, Frieling J, Weeks OL, Mullan MJ (2009) CD40/CD40L interaction induces Abeta production and increases γ-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Exp Cell Res 315:2265–2274.
22. Corder EH, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Nat Genet 3:133–138.
23. D’Onofrio G, et al. (2012) Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Discov 7:19-37.
24. Swerdlow RH, Burns JM, Khan SM (2010) The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers Dis 20:5265–5279.
25. Mohandas E, Rajmohan V, Raghunath B (2009) Neurobiology of Alzheimer disease. Wien Med Wochenschr 120:101–122.
26. Voigt C, Ait-Ghezala G, Frieling J, Weeks OL, Mullan MJ (2009) CD40/CD40L interaction induces Abeta production and increases γ-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Exp Cell Res 315:2265–2274.
27. Corder EH, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Nat Genet 3:133–138.
28. Corder EH, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Nat Genet 3:133–138.
29. Vlcek C, Ait-Ghezala G, Frieling J, Weeks OL, Mullan MJ (2009) CD40/CD40L interaction induces Abeta production and increases γ-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Exp Cell Res 315:2265–2274.
30. Corder EH, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Nat Genet 3:133–138.
31. D’Onofrio G, et al. (2012) Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Discov 7:19–37.
32. Swerdlow RH, Burns JM, Khan SM (2010) The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers Dis 20:5265–5279.
33. Mohandas E, Rajmohan V, Raghunath B (2009) Neurobiology of Alzheimer disease. Wien Med Wochenschr 120:101–122.
34. Vlcek C, Ait-Ghezala G, Frieling J, Weeks OL, Mullan MJ (2009) CD40/CD40L interaction induces Abeta production and increases γ-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Exp Cell Res 315:2265–2274.
35. Corder EH, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Nat Genet 3:133–138.
36. Vlcek C, Ait-Ghezala G, Frieling J, Weeks OL, Mullan MJ (2009) CD40/CD40L interaction induces Abeta production and increases γ-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Exp Cell Res 315:2265–2274.
37. Corder EH, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Nat Genet 3:133–138.
38. Vlcek C, Ait-Ghezala G, Frieling J, Weeks OL, Mullan MJ (2009) CD40/CD40L interaction induces Abeta production and increases γ-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Exp Cell Res 315:2265–2274.
39. Corder EH, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Nat Genet 3:133–138.
40. Vlcek C, Ait-Ghezala G, Frieling J, Weeks OL, Mullan MJ (2009) CD40/CD40L interaction induces Abeta production and increases γ-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Exp Cell Res 315:2265–2274.
41. Vlcek C, Ait-Ghezala G, Frieling J, Weeks OL, Mullan MJ (2009) CD40/CD40L interaction induces Abeta production and increases γ-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Exp Cell Res 315:2265–2274.
42. Corder EH, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Nat Genet 3:133–138.
43. Vlcek C, Ait-Ghezala G, Frieling J, Weeks OL, Mullan MJ (2009) CD40/CD40L interaction induces Abeta production and increases γ-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Exp Cell Res 315:2265–2274.
51. Lu T, et al. (2014) REST and stress resistance in ageing and Alzheimer’s disease. Nature 507:448-454.
52. Oddo S, et al. (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracerebral Abeta and synaptic dysfunction. Neuron 39:409-421.
53. Hu C, et al. (2017) Pen-2 and Presenilin are sufficient to catalyze notch processing. J Alzheimers Dis 56:1263-1269.
54. Albert JS (2009) Alzheimer’s disease. Progress Med Chem 48:133-161.
55. Hu X-T, et al. (2016) Histone deacetylase inhibitor apicidin increases expression of the amyloid precursor protein gene in ADAM10 through transcription factor USF1-mediated mechanisms. FASEB J. 10.1096/fj.201606118R.
56. Donmez G, Wang D, Cohen DE, Guarente L (2010) SIRT1 suppresses β-amyloid production by activating the amyloid gene ADAM10. Cell 142:320–332.
57. Malvaez M, et al. (2013) HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci USA 110:2647–2652.
58. Koppel I, Timmusk T (2013) Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors. Neuropharmacology 75:106–115.
59. Slentz SF, et al. (2016) Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate. eLife S;1:5092.
60. Verghese PB, et al. (2013) ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci USA 110: E1807–E1816.
61. Zhao Z, et al. (2015) Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance. Nat Neurosci 18:978–987.
62. Ait-ghezala G, et al. (2008) Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer’s disease. Cytokine 44:283–287.
63. Tan J, et al. (1999) Micropal activation resulting from CD40-CD40L interaction after β-amyloid stimulation. Science 286:2352–2355.
64. Todd Roach J, et al. (2004) Behavioral effects of CD40-CD40L pathway disruption in aged PSAPP mice. Brain Res 1015:161–168.
65. Hanson JE, et al. (2013) SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. PLoS One 8:e69964.
66. Benito E, et al. (2015) HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models. J Clin Invest 125:3572–3584.
67. Peleg S, et al. (2010) Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328:753–756.
68. Naert A, et al. (2013) Behavioural alterations relevant to developmental brain disorders in mice with neonatally induced ventral hippocampal lesions. Brain Res Bull 94:71–81.
69. Dillon GM, Qiu X, Marcus JN, Dodart J-C (2008) Excitotoxic lesions restricted to the dorsal CAG field of the hippocampus impair spatial memory and extinction learning in C57BL/6 mice. Neurobiol Learn Mem 90:426–433.
70. Kilgore M, et al. (2010) Inhibitors of class I histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 35:870–880.
71. Ricobaraza A, et al. (2009) Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer’s disease mouse model. Neuropsychopharmacology 34:1721–1732.
72. Sung YM, et al. (2013) Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer’s disease. Exp Neurol 239:192–201.
73. Gühr J, Tsai L-H (2013) The potential of HDAC inhibitors as cognitive enhancers. Annu Rev Pharmacol Toxicol 53:311–330.
74. Cruz JC, et al. (2006) p25/clin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid β in vivo. J Neurosci 26:10536–10541.
75. Fass DM, et al. (2013) Cebnobat: A novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neurpsychopharmacology 47:81-96.
76. Guan J-S, et al. (2010) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459:55–60.
77. Rumbaugh G, et al. (2015) Pharmacological selectivity within class I histone deacetylases predicts effects on synaptic function and memory rescue. Neurpsychopharmacology 40:2307–2316.
78. Min S-W, et al. (2015) Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21:1154–1162.
79. Cohen TJ, et al. (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2:252.
80. Rivieccio MA, et al. (2009) HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA 106:19599–19604.
81. Hucke E, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc Natl Acad Sci USA 100:2041–2046.
82. Huang H-L, et al. (2015) Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo. Oncotarget 6:4976–4991.
83. Pastori C, et al. (2015) The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proc Natl Acad Sci USA 112:8326–8331.
84. National Research Council (2011) Guide for the Care and Use of Laboratory Animals (National Academies Press, Washington, DC), 8th Ed.
85. Young LJ, et al. (2016) Nonmuscle myosin IIß as a therapeutic target for the prevention of relapse to methamphetamine use. Mol Psychiatry 21:615–623.
86. Arendash GW, et al. (2001) Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891:42–53.
87. Attar A, et al. (2013) A shortened Barnes maze protocol reveals memory deficits at 4–months of age in the triple-transgenic mouse model of Alzheimer’s disease. PLoS One 8:e80355.